Merck To Pay $688M To End Suits Alleging It Concealed Vytorin Data

Merck & Co. has agreed to pay $688 million to settle two shareholder class actions in federal court in Newark claiming it made false and misleading statements about the efficacy of cholesterol-reducing drug Vytorin.

This article requires premium access

This article requires premium access to The New Jersey Law Journal. Please sign in or subscribe to read the full text.